title: Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors.forename: Dalia
authors.initials: D
authors.lastname: Salem
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors.forename: Maryalice
authors.initials: M
authors.lastname: Stetler-Stevenson
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors.forename: Constance
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis*; D018365:Neoplasm, Residual / Q000175:diagnosis*; D012015:Reference Standards; D014481:United States